Group items matching

in title, tags, annotations or url

The mission of the Cystic Fibrosis Foundation (CFF) is to find a cure for Cystic Fibrosis and provide all people with the disease the opportunity to lead full, productive lives. In support of its mission, CFF is accepting applications for basic science research grants. Through the program, grants of up to $125,000 per year (plus 8 percent for indirect costs) for up to two years will be awarded in support of research dedicated to uncovering new information that contributes to the understanding of the basic etiology and pathogenesis of cystic fibrosis. Consideration also will be given to projects that provide insight that may contribute to the advancement of new Cystic Fibrosis prevention and treatment strategies. Proposals must be hypothesis driven and include enough preliminary data to justify support from the foundation.

The Cystic Fibrosis Foundation's Postdoctoral Research Fellowship Award program supports the training of postdocs in new research areas and methods related to CF as well as the collection of data that can be sued to enable their transition into an independent research career. Research projects proposed through the program should seek to develop new information that contributes to the understanding and basic etiology and pathogenesis of cystic fibrosis. Preference will be given to recent graduates and those just beginning their research careers.

 This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers.  CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis.  CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program.  Core Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research base in CF.  The NIDDK currently supports seven CF Research and Translation Centers located at institutions with documented programs of research excellence in basic and clinical CF Research.  Information about the currently funded CF Research and Translation Centers may be found at:

Research Grants are offered to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of cystic fibrosis. In addition, consideration will be given to those projects that provide insight into the development of information that may contribute to the development of new therapies for CF. All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify CFF support. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health (NIH).

Research Grants are offered to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of cystic fibrosis. In addition, consideration will be given to those projects that provide insight into the development of information that may contribute to the development of new therapies for CF. All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify CFF support. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health (NIH).

Support from the Cystic Fibrosis Foundation is intended to provide for the development of sufficient preliminary data to make cystic fibrosis-related grant applications highly competitive in the National Institutes of Health (NIH) review process and the review processes of other governmental funding agencies in other countries.

This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets. 

The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.

The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN will be composed of a Scientific and Data Coordination Center (DCC), Clinical Centers (CC) , and the NIDDK/NIH as the sponsor of the Network. ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.

The purpose of this RFA is to encourage studies on reproductive health, fertility and fertility preservation/treatment options in patients born with a serious chronic condition who can now expect to survive into adulthood healthy enough to consider their reproductive health and fertility options. The underlying pathophysiology of diseases such as sickle cell anemia, thalassemia, and cystic fibrosis, among others, and/or the cumulative effects of their treatment, can compromise reproductive health. This RFA encourages teams of scientists with expertise in the realm of the particular disease and in reproductive health and fertility to work together to understand the effects of the diseases and/or their treatments on parameters of reproductive health, and to identify ways to preserve, protect, or treat and reproductive deficits in these patients.

These awards are for developing and testing new hypotheses and/or new methods, and supporting promising new investigators as they establish themselves in research areas relevant to cystic fibrosis. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health.

The ODC is offering 38 research opportunities focusing on 29 different rare diseases. This program provides a one-year grant to support research related to a rare disease represented in the 2020 Million Dollar Bike Ride. Number of awards and dollar amounts vary per disease based on fundraising totals by each disease team. Diseases included: * Adult Polyglucosan Body Disease (APBD) * Ataxia-Telangiectasia (A-T) * BPAN- A Neurodegeneration with Brain Iron Accumulation Disorder * CADASIL * Castleman Disease * Choroideremia * Congenital Hyperinsulinism (CHI) * Congenital Muscular Dystrophy (CMD) * Charcot Maire Tooth (CMT) * Cohen Syndrome (COH) * Nonsense Mutations in Cystic Fibrosis * Dyskeratosis Congenita & Telomere Biology Disorder * Fibrous Dysplasia/McCune Albright Syndrome * Fibrodysplasia Ossificans Progressiva (FOP) * Generalized Lymphatic Anomaly (GLA; a.k.a. lymphangiomatosis) and * Gorham-Stout Disease (GSD) * Glut1 Deficiency Sundrome * Inclusion Body Myositis (IBM) * Lymphangioleiomyomatosis (LAM) * Mucopolysaccharidoses (MPS) * MPS Gene Spotlight: Mucopolysaccharidosis (MPS I) * Maple Syrup Urine Disease (MSUD) * Mitochondrial Complex 1 Deficiency Disorder - NUBPL * Neuroendocrine cell Hyperplasia of Infancy (NEHI) * Niemann Pick Type C (NPC) * Pitt Hopkins Syndrome (PTHS) * RASopathies * SETBP1 Disorder * Snyder-Robinson Syndrome (SRS) * STXBP1 Encephalopathy * TBCK Syndrome